300 Shire Way
Tel: 617 349 0200
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles with Shire Pharmaceuticals
The U.S. Food and Drug Administration (FDA) has granted Shire’s Biologics License Application (BLA) for lanadelumab (SHP643) priority review.
Shire's decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon.
Shire Continues to Uphold High Standards of Ethics and Transparency With Adoption of Open Access Policy for Publication of Shire-Supported Research
Shire's open access policy, which went into effect on January 2, 2018, was announced today at the 2018 European Meeting of International Society for Medical Publication Professionals (ISMPP) taking place in London, UK, January 23-24.
Shire will have its new CFO in March.
Shire Granted EU Marketing Authorization for ADYNOVI [Antihemophilic Factor (Recombinant), Pegylated] for Adults and Adolescents With Hemophilia A
Marketing Authorization will enable patient access to ADYNOVI throughout Europe.
Shire is splitting into two separate internal business units, Rare Disease Division and Neuroscience Division.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
Shire Canada Release: Xiidra* (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease
The approval of Xiidra is supported by the largest development program globally to-date for an investigational-stage dry eye disease therapy, consisting of five clinical trials with more than 2,500 patients.
The new facility will add about 30 percent more capacity to Shire's internal network.
Shire's New Formulation of ONCASPAR (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)
Shire today announced that the European Commission granted Marketing Authorization for lyophilized ONCASPAR, as a component of antineoplastic combination therapy in acute lymphoblastic leukemia in pediatric patients from birth to 18 years, and in adult patients.
Shire Release: Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients Through Innovative Personalized Treatment
Shire, RCSI and Science Foundation Ireland, in collaboration with the Irish Haemophilia Society, today jointly announced the initiation of a novel clinical study called "The Irish Personalised Approach to the Treatment of Haemophilia (iPATH)."
Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.
Thomas will assume his roles at Shire in early 2018 following a transition period from his current employer.
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen Technology With Baxalta, a Wholly-owned Subsidiary of Shire plc
As part of the Sublicense Agreement, Baxalta agreed to pay Xenetic a one-time payment of $7.5 million and single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A
Shire plc announced the FDA awarded Orphan Drug Designation to Shire’s gene therapy candidate SHP654 (also designated as BAX 888).
Analysts with SunTrust Robinson Humphrey recently published a research report that looked at a number of large-cap pharma companies.
Shire’s Investigational SHP609, Idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome